is vyvanse a glp-1 (Lisdexamfetamine) for ADHD: Efficacy, Safety, and What Patients Should Know Wegovy and Lisdexamfetamine: Can They

Science, 336 (6084), 10401044

Two leading investigational therapies are attracting significant attention: MariTide (Maridebart Cafraglutide / AMG 133) Amgen Novel GLP-1 receptor agonist + GIP receptor antagonist Up to ~20% mean weight loss at 52 weeks in Phase 2 studies No weight-loss plateau observed at one year Currently advancing through the Phase 3 MARITIME program Potential for monthly or even less frequent administration PF-08653944 (Berobenatide) -Pfizer Ultra-long-acting GLP-1 receptor agonist Up to 12.3% placebo-adjusted weight loss at 28 weeks in Phase 2b Continued weight reduction after transition to monthly maintenance dosing No plateau observed at the 28-week analysis Designed to simplify long-term obesity management through monthly dosing Key Takeaway While MariTide currently leads in weight-loss efficacy, Pfizers Berobenatide highlights the potential of a streamlined, pure GLP-1 approach optimized for monthly maintenance and adherence

These include: Broccoli Cauliflower Cabbage Garlic Onions Brussels sprouts Eggs Lean proteins Vitamin C-rich foods such as oranges, kiwi, guava, and strawberries may also support glutathione activity

pylori -induced carcinogenesis via its attenuating the effect on the H